Outlook Therapeutics, Inc.
OTLK- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001649989
In the last 90 days, Outlook Therapeutics, Inc. insiders filed 4 open-market purchases and 0 sales; 68 institutions reported holding it in 13F filings for Q2 2026, worth $32.2M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Outlook Therapeutics, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 49 | 63 | +14 |
| Shares | 13.5M | 20.2M | +6.78M (+50.3%) |
| Value | $30.3M | $50.4M | +$20.1M (+66.4%) |
New holders (28)
Institutions that held Outlook Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
Sold out (14)
Institutions that held Outlook Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Renaissance Technologies LLC | 832,558 | $1.87M |
| Millennium Management LLC | 200,013 | $450.0K |
| Susquehanna International Group, LLP | 165,835 | $373.0K |
| ExodusPoint Capital Management, LP | 141,894 | $319.0K |
| Marshall Wace, LLP | 80,821 | $182.0K |
| LMR Partners LLP | 54,980 | $124.0K |
| HRT Financial LP | 28,686 | $64.0K |
| GWM Advisors LLC | 20,000 | $45.0K |
| Balyasny Asset Management LLC | 13,766 | $31.0K |
| Capstone Investment Advisors, LLC | 12,562 | $28.0K |
| Two Sigma Securities, LLC | 12,449 | $28.0K |
| Sciencast Management LP | 12,300 | $27.0K |
| Jefferies Group LLC | 11,200 | $25.2K |
| Valeo Financial Advisors, LLC | 1,000 | $2.00K |